Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoki Kashihara

Showing results (191-200 of 206) with videos related to

Pageof 21
Sort By:
Plos Medicine|June 29, 2016
The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled TrialJun-Ichi Oyama, Toyoaki Murohara, Masafumi Kitakaze, et al.
Clinical Kidney Journal|July 12, 2021
Methods and rationale of the DISCOVER CKD global observational studyRoberto Pecoits-Filho, Glen James, Juan Jesus Carrero, et al.
Diabetes, Obesity & Metabolism|May 8, 2024
Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease DatabaseTomohiko Kanaoka, Hiromichi Wakui, Yuichiro Yano, et al.
Clinical and Experimental Nephrology|July 6, 2004
A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey)Toshiaki Shibasaki, Akio Koyama, Akira Hishida, et al.
Diabetes Research and Clinical Practice|June 15, 2026
B-type natriuretic peptide level reduction and its predictors following sodium-glucose cotransporter 2 inhibitor treatment in patients with diabetic kidney disease: a Japan Chronic Kidney Disease Database Extension analysisTakanori Nagahiro, Masaaki Konishi, Tomohiko Kanaoka, et al.
The New England Journal of Medicine|March 30, 2026
Iptacopan in IgA Nephropathy - Final 24-Month DataJonathan Barratt, Necmi Eren, Naoki Kashihara, et al.
Diabetes Care|October 1, 2021
Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease DatabaseHajime Nagasu, Yuichiro Yano, Hiroshi Kanegae, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 4, 2025
Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney DiseaseJ Bradley Layton, Ryan Ziemiecki, Catherine B Johannes, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 17, 2024
Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort StudyCatherine B Johannes, Ryan Ziemiecki, Manel Pladevall-Vila, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 31, 2020
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C Wheeler, Bergur V Stefansson, Mikhail Batiushin, et al.
Pageof 21

Showing results (191-200 of 206) with videos related to

Sort By:
Pageof 21
Plos Medicine|June 29, 2016
The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled TrialJun-Ichi Oyama, Toyoaki Murohara, Masafumi Kitakaze, et al.
Clinical Kidney Journal|July 12, 2021
Methods and rationale of the DISCOVER CKD global observational studyRoberto Pecoits-Filho, Glen James, Juan Jesus Carrero, et al.
Diabetes, Obesity & Metabolism|May 8, 2024
Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease DatabaseTomohiko Kanaoka, Hiromichi Wakui, Yuichiro Yano, et al.
Clinical and Experimental Nephrology|July 6, 2004
A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey)Toshiaki Shibasaki, Akio Koyama, Akira Hishida, et al.
Diabetes Research and Clinical Practice|June 15, 2026
B-type natriuretic peptide level reduction and its predictors following sodium-glucose cotransporter 2 inhibitor treatment in patients with diabetic kidney disease: a Japan Chronic Kidney Disease Database Extension analysisTakanori Nagahiro, Masaaki Konishi, Tomohiko Kanaoka, et al.
The New England Journal of Medicine|March 30, 2026
Iptacopan in IgA Nephropathy - Final 24-Month DataJonathan Barratt, Necmi Eren, Naoki Kashihara, et al.
Diabetes Care|October 1, 2021
Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease DatabaseHajime Nagasu, Yuichiro Yano, Hiroshi Kanegae, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 4, 2025
Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney DiseaseJ Bradley Layton, Ryan Ziemiecki, Catherine B Johannes, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 17, 2024
Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort StudyCatherine B Johannes, Ryan Ziemiecki, Manel Pladevall-Vila, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 31, 2020
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C Wheeler, Bergur V Stefansson, Mikhail Batiushin, et al.
Pageof 21